Abstract:Background It is thought that Rheumatoid arthritis (RA) arises from a breakdown in immunological self-tolerance. We have givena direct evidence for this conceptionthat absolute number of peripheral CD4+Regulatory T-cells (Tregs) decreased inRA patients[1]. Furthermore, rapamycin can significantly induce immune tolerance through up-regulate Tregs and down-regulate Th17 cells[2]. Objectives To investigate the effect of rapamycin on the absolute numbers of Th17 and Treg cells and on maintenance of disease remission in RA patients instead of DMARDs. Methods Thirty-two patients, who achieved remission(DAS28 ≤2.6) by the treatment with two kinds of DMARDs for more than half a year, received rapamycin at a dose of 0.5 mg every other dayfor 12 weeks. Before and after treatment with rapamycin, thediseaseactivity and immunological assessments of them were performed. In this study, BD Trucount tubes with the lyophilized pellet of a known number of internal counting beads were used for determining absolute counts of total CD4+ T cells in peripheral blood and then calculating the absolute number of Th17 cells and CD4+Tregs. Results At week 12, 65.6% of the patients maintained remission (DAS28 ≤2.6). TheDAS28 was increased from a median of 2.03(at week 0) to 2.15(at week 12) (p>0.05). The absolute numberof Treg cells was increased significantly from a median of 22.16(at week 0) to 32.19(at week 12) (P=0.039). The absolute number of Th17 cells was decreased from a median of5.98(at week 0) to 5.56(at week 12) (p>0.05). The ratio of Th17/Treg cells was also decreased from a median of 0.245(at week 0) to 0.19(at week 12) (p>0.05). At the same time, the mean dosage of prednisone decreased from 6.29 mg/d to 5.35 mg/d and thatof DMARDs were also reduced from93.75% to 56.25%. Conclusions Rapamycin was effective in the maintenance of remission(DAS28 ≤2.6)by increase of Treg cells and correcting the imbalance of Th17/Treg cells. Meantime, the mean dosage of conventional drugs such as glucocorticoid and DMARDs gradually decreased. In the future, rapamycin may replace current immunosuppressant for treatment of RA. References [1] Niu H, Li Z, He J, et al. Rapamycin selectively increases circulating Treg cells and modulates the imbalance of Th17/Treg cells in patients with low active rheumatoid arthritis. [2] Yang X, Yao Q, Hu X, et al. Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice. Zhonghua Yi Xue Za Zhi2015Aug 11;95(30):2469–73. Disclosure of Interest None declared

Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells.

Rapamycin-resistant effector T-cell therapy

Characterization of Protective Human CD4CD25 FOXP3 Regulatory T Cells Generated with IL-2, TGF-β and Retinoic Acid.

Engineered Regulatory T Cells Prevent Graft-Versus-host Disease While Sparing the Graft-Versus-leukemia Effect after Bone Marrow Transplantation.

Efficient Generation of Human Alloantigen-Specific CD4+ Regulatory T Cells from Naive Precursors by CD40-activated B Cells

Rapamycin Together with TGF-β1, IL-2 and IL-15 Induces the Generation of Functional Regulatory Γδt Cells from Human Peripheral Blood Mononuclear Cells

Ex Vivo Expansion of Human Tregs Specific for Alloantigens Presented Directly or Indirectly.

Large-scale in vitro expansion of human regulatory T cells with potent xenoantigen-specific suppression

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation.

Human Regulatory T Cells Against Minor Histocompatibility Antigens: Ex Vivo Expansion for Prevention of Graft-Versus-host Disease.

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease.

Mtor Inhibitor Rapamycin Induce Polymorphonuclear Myeloid-Derived Suppressor Cells Mobilization and Function in Protecting Against Acute Graft-Versus-host Disease after Bone Marrow Transplantation

[Influence of Mouse Genetic Engineering Regulatory T Cells Infusion on Post-Allogeneic Bone Marrow Transplantation Acute Graft-Versus-host Disease in Mice].

Enhanced suppression of the xenogeneic T-cell response in vitro by xenoantigen stimulated and expanded regulatory T cells

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

CD4+ and CD8+ Regulatory T Cells Generated Ex Vivo with IL-2 and TGF-β Suppress a Stimulatory Graft-versus-Host Disease with a Lupus-Like Syndrome

Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro